Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer
WALTHAM, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the initiation of the CONTERNO study, a global, randomized Phase 3 trial more...
Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit
Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit – Representatives from Actinium’s R&D and Clinical Development teams to discuss Actinium’s experience developing targeted radiotherapies on panels focused on more...
Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx(TM) in China
Companies complete second and most critical of three steps in Technology Transfer Oncocyte receives $2M milestone payment IRVINE, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the more...
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / December 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that the U.S. Food and Drug Administration more...
Anixa (ANIX) COVID Compounds Prove Effective Against Omicron
Anixa Biosciences, Inc. ANIX announced that its potential compounds, which are being developed to treat COVID-19, are anticipated to be effective against the Omicron variant of COVID-19. Please note that the compounds are being developed more...
Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche’s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab
HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the initiation of patient recruitment for more...
Evofem Biosciences to Adjourn Special Meeting of Stockholders on December 8, 2021
Evofem Biosciences to Adjourn Special Meeting of Stockholders on December 8, 2021 — Meeting to Reconvene on December 15, 2021 — PR Newswire SAN DIEGO , Dec. 8, 2021 /PRNewswire/ — Evofem Biosciences, Inc. (NASDAQ: EVFM) more...
Find Strong Cheap Stocks Under $10 to Buy in December
The market popped to start the week, with the Dow leading the charge, as buyers came back in following Friday’s big downturn. Stocks continued to storm back Tuesday, with the tech-heavy Nasdaq up over 3% more...
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®
ImprimisRx to assume full responsibility for U.S. sales and marketing activities for DEXYCU® and absorb the majority of EyePoint’s DEXYCU commercial organization; EyePoint to retain DEXYCU NDA, revenue recognition, manufacturing and distribution responsibilities for all more...
Daré Announces FDA Approval of XACIATO(TM) (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
Prescribing information supports positioning of XACIATO as a first line option for the treatment of bacterial vaginosis This marks the first FDA-approved product in Daré’s portfolio of potential first in category development candidates Strategic partnering more...